GlassScriptPhysician profile
Virgil Pate
NPI 1518948751
$2,310.75
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $1,415 · 2021: $14.17 · 2022: $34.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,302.00 | 2020 | |
| Astellas Pharma US INC | $521.63 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $154.96 | 2019 | |
| Janssen Biotech, INC. | $56.73 | 2019 | |
| Abbvie INC. | $49.99 | 2019-2022 | |
| 180 Medical, INC. | $48.21 | 2019 | |
| Allergan, INC. | $36.25 | 2019-2020 | |
| Genzyme Corporation | $32.56 | 2019 | |
| Boston Scientific Corporation | $28.44 | 2019 | |
| Pfizer INC. | $23.68 | 2019 | |
| Duchesnay USA Incorporated | $23.33 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.44 | 2019 | |
| Blue Earth Diagnostics | $12.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virgil Pate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.